Telmisartan Market Statistics 2020-2027:
The global telmisartan market size was valued at $3,453 million in 2019, and is projected to reach $4,258 million by 2027, registering a CAGR of 3.4% from 2020 to 2027. Telmisartan drug is a non-peptide angiotensin receptor blockers (ARBs) intended for treatment of hypertension and cardiovascular risk reduction. It is used alone or in combination with other agents such as hydrochlorothiazide and amlodipine. Telmisartan is available in three different strengths tablets such as 20 mg, 40 mg, and 80 mg. Telmisartan is indicated for the treatment of mild to moderate hypertension condition. It works by relaxing blood vessels so that blood can flow more easily. However, it has some side effects which include dizziness, cough, lightheadedness, sinus pain and others.
Increase in prevalence of high blood pressure (hypertension), surge in geriatric population, and rise in government initiatives for spreading awareness about blood pressure diseases are the factors that are expected to drive the growth of the market. For instance, in May 2017, Argentinian Society of Hypertension (SAHA) joined in campaigns such as ‘May Measurement Month & World Hypertension Day’ for making awareness among population about hypertension and its management. In addition, rise in marketing approvals for generic versions of telmisartan, increase in sedentary lifestyle, and surge in incidences of chronic diseases such as diabetes and kidney disease, are expected to drive the growth of the telmisartan market. However, drug shortages are expected to restrain the growth of the telmisartan market. Conversely, surge in research related to telmisartan drug in emerging economies is expected to offer lucrative opportunities during the forecast period.
The World Health Organization (WHO) on January 30, 2020, declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. Telmisartan tablets manufacturing and distributing companies have been affected by COVID-19 to a limited extent, owing to shut down in various COVID-19 affected countries and rise in number of healthcare workers falling ill in the wake of the COVID-19 pandemic, leading to supply shortage.
Telmisartan Market Segmentation
The global telmisartan market is segmented into indication, distribution channel, and region. On the basis of indication, the market is categorized into hypertension and cardiovascular risk reduction. Depending on distribution channel, it is segregated into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Indication Segment Review
Presently, on the basis of indication, the hypertension is a major revenue contributor, and is projected to grow significantly during the forecast period. Increase in prevalence of hypertension, rise in demand for antihypertensive drugs, and surge in awareness about hypertension and its management by organizing global level campaigns boosts the growth of the market. Moreover, availability of better treatment options for hypertension, increase in number of product approvals, and rise in geriatric population suffering from hypertension are the other factors that drive the growth of the market.
By Indication
Hypertension segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.
Distribution Channel Segment Review
Depending on distribution channel, the hospital pharmacies segment is the major shareholder in the global telmisartan market, owing to surge in number of hospitalized hypertension patients, increase in number of hospital pharmacies worldwide, and improvement in structure of hospital pharmacies in the emerging countries such as China and India. Moreover, telmisartan drug is a prescription-based medication, which is mostly prescribed by the specialized healthcare professionals available in hospitals, thereby boosting the growth of this segment. On the contrary, the online pharmacies segment is expected to exhibit the highest growth rate during the forecast period, owing to increase in awareness of online pharmacy, rise in preference for online purchasing of drugs, and surge in the use of internet across the globe. Moreover, online pharmacies offer various advantages such as more convenience, fewer expenses, easy access to patient reviews, and price comparisons, which drive the market growth.
By Distribution Channel
Hospital Pharmacies segment is projected as one of the most lucrative segment.
Regional Segment Review
Asia-Pacific presents lucrative opportunities for key players operating in the telmisartan market, owing to increase in number of hypertension patients in emerging economies, rise in adoption of antihypertensive drugs, development of the R&D sector, rise in healthcare reforms, and technological advancements in pharmaceutical drug manufacturing, Moreover, rise in demand for telmisartan tablets, surge in funding from government and non-government sectors to create awareness about hypertension and cardiovascular diseases, rise in number of hospital pharmacies and online pharmacies, and presence of high population base contributes toward growth of the market. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive the growth of the telmisartan market in the region.
By Region
Asia-Pacific region would exhibit the highest CAGR of 5.2% during 2019-2026.
Competitive Analysis
The key players profiled in this report include Abbott Laboratories, Aurobindo Pharma, Boehringer Ingelheim International GmbH, Cipla Inc., Glaxosmithkline Plc (GSK), Mylan N.V., Sanofi, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd. (Actavis Generics), and Zydus Cadila.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the telmisartan market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers telmisartan market analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global telmisartan market growth.
Telmisartan Market Report Highlights
| Aspects | Details |
 By INDICATION |
|
 By DISTRIBUTION CHANNEL |
|
 By Region |
|
 Key Market Players | MYLAN N.V, TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS), CIPLA INC, BOEHRINGER INGELHEIM INTERNATIONAL GMBH, AUROBINDO PHARMA, ZYDUS CADILA, ABBOTT LABORATORIES, GLAXOSMITHKLINE PLC (GSK), SANOFI, SUN PHARMACEUTICAL INDUSTRIES LIMITED |
Analyst Review
Telmisartan is an angiotensin receptor blocker (ARB) used alone or in combination with hydrochlorothiazide and amlodipine for treatment of hypertension and cardiovascular risk reduction. It is available in different strengths tablets such as 20 mg, 40 mg, and 80 mg.
The utilization of telmisartan drug has witnessed significant growth, owing to surge in incidence of hypertension and cardiovascular diseases worldwide. Furthermore, other factors such as rise in geriatric population suffering from high blood pressure, surge in generic telmsartan tablets approvals, surge in awareness related to complication of hypertension, and sedentary lifestyle are the factors that fuel the growth of the market. However, drug shortages are expected to restrain the growth of the telmisartan market.
Telmisartan is indicated for the treatment of mild to moderate hypertension and cardiovascular risk reduction.
Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 6.0%. This is due to increase in number of hypertension patients in emerging economies, rise in adoption of antihypertensive drugs, development of the R&D sector, rise in healthcare reforms, and technological advancements in pharmaceutical drug manufacturing, Moreover, rise in demand for telmisartan tablets, and surge in funding from government and non-government sectors to create awareness about hypertension and cardiovascular diseases.
The total market value of Telmisartan market is $3,453.13 million in 2019.
The forcast period for Telmisartan market is 2020 to 2027
Top companies such as Abbott Laboratories, Boehringer Ingelheim International GmbH, Glaxosmithkline Plc (GSK), Mylan N.V., Teva Pharmaceutical Industries Ltd. (Actavis Generics), and Zydus Cadila held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
The market value of Telmisartan market in 2020 is $3,366.81 million.
Hypertension segment is the most influencing segment owing to surge in prevalence of hypertension across the globe, rise in awareness related to the use of telmisartan for the treatment of high blood pressure.
The base year is 2019 in Telmisartan market
The growth of the global telmisartan market is driven by surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension and cardiovascular is another major factor that fuels the growth of the market. In addition, surge in geriatric population and sedentary lifestyle act as key drivers of the global market. Moreover, increase in approval for abbreviated new drug application (ANDA) for manufacturing of generic telmisartan tablets and rise in cases of chronic kidney disease is expected to propel growth of telmisartan market.
Loading Table Of Content...
